<div id="readability-page-1">Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 603.54% and currently trading at $930.15. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years, Eli Lilly went from a $100 billion market capitalization to $740 billion today, which also makes it a potential stock split stock. But as investors, we care about the stock price years down the line, what Eli Lilly will do in the next 3 to 5 years and beyond. That is why 24/7 Wall Street looks at projected revenue and net income to give you our best estimate of future stock prices from 2025 to 2030. Other “experts” look at past growth rates and assign future stock prices to those past numbers. However, we will walk you through our assumptions and give you the key drivers we see propelling Eli Lilly’s stock in the future. <img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/10/imageForEntry31-0VG.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1366" height="767" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2022/10/imageForEntry31-0VG.jpg"/> <h2>Eli Lilly’s Recent Stock Success </h2> How did Eli Lilly’s stock price soar so much in the past few years? Let’s take a look at the numbers: <table> <tbody> <tr> <td></td> <td>Share Price</td> <td>Revenues*</td> <td>Net Income*</td> </tr> <tr> <td>2016</td> <td>$80.36</td> <td>$21.22</td> <td>$2.74</td> </tr> <tr> <td>2017</td> <td>$77.55</td> <td>$19.94</td> <td>($0.21)</td> </tr> <tr> <td>2018</td> <td>$122.13</td> <td>$21.49</td> <td>$3.23</td> </tr> <tr> <td>2019</td> <td>$140.83</td> <td>$22.32</td> <td>$8.32</td> </tr> <tr> <td>2020</td> <td>$206.46</td> <td>$24.54</td> <td>$6.19</td> </tr> <tr> <td>2021</td> <td>$238.31</td> <td>$28.32</td> <td>$5.58</td> </tr> <tr> <td>2022</td> <td>329.07</td> <td>$28.54</td> <td>$6.25</td> </tr> <tr> <td>2023</td> <td>$745.91</td> <td>$34.12</td> <td>$5.24</td> </tr> </tbody> </table> *Revenue and Net Income in Billions Since 2016, Eli Lilly’s revenue grew by 60% but income grew by 91%. Typically you wouldn’t expect a company growing at its top line by 7% annually to see an 828% increase in share price, however, investor sentiment for the next line of drugs front ran the stock price. For example, in 2016 Eli Lilly was trading 13 times the trailing 12 months earnings and the market has increased its valuation each year and currently trades at a 125 times earnings multiple. This raises the valid question, is Eli Lilly overvalued or will future revenues make up for the expensive valuation? <h2>3 Key Drivers of Eli Lilly Stock</h2> <ol> <li>Innovated Drug Pipeline: The current drug pipeline is loaded with several very high-potential drugs in development. Mounjaro, Zepbound, and Jardiance in the cardiometabolic category, Taltz in immunology, and Verzenio in oncology are the future of Eli Lilly’s growth. While the aforementioned are the safer bets, the company has a handful of other drugs that could hold blockbuster potential. </li> <li>Strategic Acquisitions: The acquisition of Morphic, with its promising drug candidate MORF-057, is a testament to Lilly’s strategic vision. This drug, if successful in late-stage trials, could become a major success in the treatment of inflammatory bowel disease (IBD). Lilly’s focus on acquiring mid-sized companies (13 since 2020) with promising pipelines has bolstered its own research and development efforts, positioning it well for future growth.</li> <li>Operational Efficiency: With a sound balance sheet, Eli Lilly should continue to improve operational efficiency and manage costs to have net income growth rates above revenue growth.</li> </ol> <img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2021/11/imageForEntry14-5mH.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1366" height="767" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2021/11/imageForEntry14-5mH.jpg"/> <h2>Eli Lilly (LLY) Stock Price Prediction in 2025</h2> The current Wall Street consensus 1-year target of Eli Lilly stock is $898, which is -3.46% higher than today’s price of $930.15. Of the 26 analysts covering Eli Lilly stock, the current rating is 1.71 or “Outperform” with 1-year price targets as high as $1,100 and as low as $540.00. 24/7 Wall Street sets its 1-year price target at $1,040. Taking a look at the sum of its parts, we see Eli Lilly’s vertices valued as follows: <table> <tbody> <tr> <td>Endocrinology</td> <td>$735/ share</td> </tr> <tr> <td>Oncology</td> <td>$122/ Share</td> </tr> <tr> <td>Cardiovascular</td> <td>$4/ Share</td> </tr> <tr> <td>Neuroscience</td> <td>$16/ Share</td> </tr> <tr> <td>Immunology</td> <td>$38/ Share</td> </tr> <tr> <td>Others and Pipeline</td> <td>$110/ Share</td> </tr> <tr> <td>Cash</td> <td>$17/ Share</td> </tr> </tbody> </table> <h2>Eli Lilly’s Share Price Estimates 2025-2030</h2> Valuing Eli Lilly’s stock price for the coming years, we will take a look at expected revenue and net income and give our best estimate of the market value of the company by assigning a price to earnings multiple. <table> <tbody> <tr> <td></td> <td>Revenue</td> <td>Net Income</td> <td>EPS</td> </tr> <tr> <td>2025</td> <td>$52.8</td> <td>$17.29</td> <td>19.11</td> </tr> <tr> <td>2026</td> <td>$62.5</td> <td>$22.49</td> <td>25.03</td> </tr> <tr> <td>2027</td> <td>$70.87</td> <td>$27.12</td> <td>30.39</td> </tr> <tr> <td>2028</td> <td>$80.68</td> <td>$32.2</td> <td>25.97</td> </tr> <tr> <td>2029</td> <td>$87.99</td> <td>$36.45</td> <td>40.58</td> </tr> <tr> <td>2030</td> <td>$96.67</td> <td>$41.12</td> <td>46.29</td> </tr> </tbody> </table> *Revenue and net income reported in billions <img src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2024/08/2024-8-16-LLY-Stock-Price.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1600" height="900" original-src="https://imageproxy.pbkrs.com/https://247wallst.com/wp-content/uploads/2024/08/2024-8-16-LLY-Stock-Price.png"/> <h2>Eli Lilly Price Forecast and Prediction for 2025:</h2> Price Target: $1140.00 Upside: 22.56% We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong revenue growth of 18.37% to $52.80 billion and net income expansion to $17.29 billion, continuing the upward trajectory from previous years. <h2>Eli Lilly Price Forecast and Prediction for 2026:</h2> Price Target: $1250 Upside: 34.39% For 2026, we anticipate a P/E ratio of 50 with an EPS of $25.03, leading to a price target of $1251.50. This reflects significant revenue growth of 18.37% to $62.50 billion and an increase in net income to $22.49 billion, driving higher earnings per share. <h2>Eli Lilly Price Forecast and Prediction for 2027:</h2> Price Target: $1520.00 Upside: 63.41% In 2027, we project the P/E ratio to remain at 50, with EPS increasing to $30.39. This results in a price target of $1519.50. Continued revenue growth of 13.39% to $70.87 billion and net income expansion to $27.12 billion justifies this substantial increase in stock price. <h2>Eli Lilly Price Forecast and Prediction for 2028:</h2> Price Target: $1300.00 Upside: 39.76% With an EPS of $25.97 and a P/E ratio of 50 in 2028, we forecast the stock price to be $1298.50. A slight dip in EPS growth is expected, but sustained strong performance in net income to $32.20 billion and revenue growth of 13.84% to $80.68 billion keeps the stock highly valued. <h2>Eli Lilly Price Forecast and Prediction for 2029:</h2> Price Target: $1623.00 Upside: 74.49% By 2029, we estimate Eli Lilly’s EPS to rise to $40.58, with the P/E ratio adjusting to 40. This gives us a price target of $1623.20. The continuous revenue growth of 9.06% to $87.99 billion and net income expansion to $36.45 billion supports this higher valuation. <h2>Eli Lilly Price Forecast and Prediction for 2030:</h2> Price Target: $1850.00 Upside: 98.89% By 2030, we estimate Eli Lilly’s EPS to rise to $46.29, with the P/E ratio adjusting to 40. This gives us a price target of $1851.60. The continuous revenue growth of 9.86% to $96.67 billion and net income expansion to $41.12 billion supports this higher valuation. <table> <tbody> <tr> <th>Year</th> <th>Price Target</th> <th>% Change From Current Price</th> </tr> <tr> <td>2025</td> <td>$1140.00</td> <td>Upside of 22.56%</td> </tr> <tr> <td>2026</td> <td>$1250.00</td> <td>Upside of 34.39%</td> </tr> <tr> <td>2027</td> <td>$1520.00</td> <td>Upside of 63.41%</td> </tr> <tr> <td>2028</td> <td>$1300.00</td> <td>Upside of 39.76%</td> </tr> <tr> <td>2029</td> <td>$1623.00</td> <td>Upside of 734.49%</td> </tr> <tr> <td>2030</td> <td>$180.00</td> <td>Upside of 98.89%</td> </tr> </tbody> </table> <h2>Recent Eli Lilly Stock Updates and News</h2> 8/15/2024 Eli Lilly has opened the Lilly Seaport Innovation Center (LSC) in Boston. This 12-story state-of-the-art research and development houses laboratories, office space, and research facilities dedicated to advancing the company’s work on RNA and DNA-based therapies. The center will also focus on developing drug targets for cardiovascular issues, obesity, and diabetes. 8/14/2024 With the increase in Eli Lilly’s weight-loss drug supply, the company has now issued a cease-and-desist order to telehealth companies to stop the promotion of copycat drugs. 8/12/2024 Eli Lilly and Purdue University have announced a new partnership to accelerate the development of new medicines and technologies. Known as the Eli Lilly and Purdue University Research Alliance Center (LPRC), this expanded collaboration will focus on improving each stage of pharmaceutical research. 8/9/2024 Eli Lilly announced its plans yesterday to submit the company’s research and recent clinical trials on how Zepbound affects heart health to the FDA. They have also submitted approval requests for Zepbound as a treatment for Sleep apnea. 8/8/2024 Stock is soaring following Eli Lilly’s second-quarter financial report. The company’s worldwide revenue in the first six months of this year was $11.30 billion — a significant %36 increase compared to the same time last year. Eli Lilly made more money on new products, including Mounjaro and Zepbound. Verzenio’s sales also increased 44% to $1.3 billion. Analysts previously estimated $2.74 earnings per share, but overall Eli Lilly’s adjusted earnings resulted in $3.92 per share. 8/7/2024 Amid its recent success in weight loss and diabetes medications, Eli Lilly is entering a new field: producing nuclear isotopes, which are needed for a new type of cancer treatment. The company invested $10 million into an isotope supplier, Inoetix. Inoetix anticipates that by the end of the year, it will be able to produce around one curie of actinium each week. This will provide enough for approximately 26,000 annual patient treatments. 8/6/2024 All eyes are on Eli Lilly as investors eagerly await the company’s quarterly earnings report, due out Thursday. Analysts predict approximately $10 billion in sales and earnings per share of around $2.70. The company’s future prospects look promising, especially given the anticipated strong performance of its diabetes drug (Mounjaro) and weight loss drug (Zephbound) during the past quarter. 8/5/2024 According to the U.S. Food and Drug Administration’s drug shortage database, Eli Lilly’s drugs Zepbound and Mounjaro are now available in all doses in the United States. Meanwhile, investors are closely watching Eli Lilly as they eagerly await the company’s earnings report this week. Experts predict strong sales and profits for the quarter due to the success of its obesity and diabetes drugs. 8/2/2024 Eli Lilly’s stock price is down today, despite a surge yesterday following the announcement of promising results from the company’s SUMMIT phase 3 clinical trial. Investors remain cautious as they await the company’s second-quarter financial report next week. Additionally, Eli Lily has reported that the Zepbound shortage is nearing its end. This is positive news for the company, as the FDA declared both Zepbound and Mounjaro in limited supply this past April. As a result, smaller companies began selling cheaper and unapproved off-brand versions of these medications. However, with the Zepbound shortage easing, Eli Lily is poised to regain its market share and profitability over these smaller competitors. 8/1/2024 Eli Lilly shares are climbing following the company’s announcement regarding their weight loss drug, Zepbound. The drug showed promising results in treating people with heart failure and obesity. Approximately half of people with heart failure suffer from a specific type, referred to as HFpEF. In the United States, many of these people are also overweight. In the recent SUMMIT phase 3 clinical trial, adverse risks and outcomes were 38% lower in those treated with the Zepbound compared to patients given a placebo. This led to a 3.5% increase in Eli Lilly shares before the market opened this morning. 7/31/2024 DexCom’s stock plummeted by 40% following its earnings report, prompting a JPMorgan analyst to question whether the stock price decline was linked to the increasing sales of GLP-1 medications. Eli Lilly’s Mounjaro and other GLP-1 drugs are in short supply as demand for these weight loss treatments continues to surge. 7/30/2024 Amid Viking Therapeautic’s recent weight loss drug success, Eli Lilly is still a top player in the market. JPMorgan predicts the company could increase by 25% from its current price. 7/29/2024 Eli Lilly’s stock is up almost 3% with today’s market open and continues to climb steadily, despite the recent success of Viking Therapeutics’ competing weight loss drug. Investors remain cautious as they await the company’s quarterly earnings report, scheduled for release on August 8th. While analysts debate which biotech company will ultimately dominate the weight loss drug market, it’s clear that Eli Lilly is still a major contender. 7/26/2024 Yesterday, Eli Lilly’s shares dropped 4.5%, which is the lowest we’ve seen since May. However, while Viking Therapeutic’s announcement has caused a significant loss in value this past week ($120 billion), Eli Lilly is still up over 30% year-to-date and up over 70% in the past year. 7/25/2024 Eli Lilly’s stock prices dropped slightly because Viking Therapeutics (VKTX) announced that recent trials of their new weight loss drugs are showing promising results. Viking Therapeutics’ new weight loss drugs could potentially challenge Eli Lilly’s Mounjaro. 7/23/2024 Eli Lilly will announce 2nd quarter earnings on August 8th and analysts are anticipating $2.766 earnings per share which is 31% over last year’s earnings for the same quarter. Revenue is expected to come in at $10 billion, which is a 20% year-over-year gain. 7/22/2024 Eli Lilly announced Chinese approval for its weight loss drug, tirzepatide. This intensifies competition with Novo Nordisk, whose weight loss drug Wegovy was approved in China in June. Both companies are vying for the growing weight-loss market, projected to exceed $100 billion globally by the decade’s end. <div> <h2>“The Next NVIDIA” Could Change Your Life</h2> If you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over. The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.” Click here to download your FREE copy. </div> The post Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 appeared first on 24/7 Wall St..</div>

Eli Lilly's (NYSE: LLY) stock has surged 603.54% since 2020, recently trading at $649.15. The company experienced growth from a billion market cap to a billion. Investment outlook focuses on the next five years with projected revenue and net income impacting future valuations. Key drivers of stock growth include an innovative drug pipeline, strategic acquisitions, and improved operational efficiency. Current analyst targets set the 1-year price at $648.71, with a consensus rating of "Outperform." Future estimations show revenue and earnings-per-share forecasts for 2025-2030 to guide performance expectations.